{"id":390068,"date":"2021-03-29T00:00:00","date_gmt":"2021-03-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0001-2020-biopharma-breast-cancer-disease-landscape-and-forecast-g7-2020\/"},"modified":"2026-03-31T10:43:41","modified_gmt":"2026-03-31T10:43:41","slug":"dlsfon0001-2020-biopharma-breast-cancer-disease-landscape-and-forecast-g7-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0001-2020-biopharma-breast-cancer-disease-landscape-and-forecast-g7-2020\/","title":{"rendered":"Breast Cancer | Disease Landscape and Forecast | G7 | 2020"},"content":{"rendered":"<p>The breast cancer market is rapidly evolving and presents new commercial opportunities for drug developers. CDK4\/6 inhibitors (Pfizer\u2019s Ibrance, Novartis\u2019s Kisqali, and Eli Lilly\u2019s Verzenio \/ Verzenios) are creating new dynamics in the metastatic HR-positive \/\u00a0HER2-negative treatment practice. In HER2-positive breast cancer, HER2-targeting drugs in development are forecast to enter the market, while sales of current HER2-targeting agents will be impacted as a result of competition, label expansions, biosimilar entries, and new trials leading to changes in treatment guidelines. Furthermore, the approval of PARP inhibitors (AstraZeneca \/ Merck &#038; Co.\u2019s Lynparza and Pfizer\u2019s Talzenna), PD-1-targeting agents (Roche \/ Genentech \/ Chugai\u2019s Tecentriq), PI3K inhibitors (Novartis\u2019s Piqray), HER2-targeting agents (Daiichi Sankyo \/ AstraZeneca\u2019s Enhertu, Seagen\u2019s Tukysa, and MacroGenics\u2019 Margenza), TROP2-targeting antibody-drug conjugates (Immunomedics\u2019 Trodelvy), and the anticipated entry of other agents from these drug classes will diversify treatment options, especially for triple-negative breast cancer.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>What is the size of the drug-treatable breast cancer population, and how will drug-treatment rates change over time?<\/li>\n<li>What is the expected market impact of recent drug approvals, such as Tecentriq, Piqray, Enhertu, Tukysa, and Trodelvy on the various subpopulations of breast cancer?<\/li>\n<li>What are the most promising agents in the pipeline, and how will they shape the future of the breast cancer market?<\/li>\n<li>What are the drivers and constraints in the breast cancer market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Content Highlights<\/strong><\/p>\n<ul>\n<li>Geographies: United States, EU5, Japan<\/li>\n<li>Primary Research: 19 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other DRG research<\/li>\n<li>Epidemiology: Incidence of breast cancer by country, segmented by HR and HER2 status, staging, and line of therapy<\/li>\n<li>Forecast: 10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2029, segmented by brands \/ biosimilars \/ generics and market-relevant drug-treatable populations<\/li>\n<li>\u00a0Emerging Therapies: Phase III\/PR: 15\u00a0drugs; coverage of select Phase I and II products<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390068","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-breast-cancer","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390068","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390068\/revisions"}],"predecessor-version":[{"id":576431,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390068\/revisions\/576431"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390068"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}